Loading...
TELA Bio Q1 2025 Earnings Report
TELA Bio reported its financial results for the first quarter ended March 31, 2025, showing revenue growth and a focus on profitability.
Key Takeaways
TELA Bio delivered revenue of $18.5 million in Q1 2025, an increase of 12% year-over-year, driven by increased demand for OviTex® products and new customer acquisitions. Despite a decrease in gross margin due to inventory adjustments, the company reiterated its full-year 2025 revenue guidance.
Revenue reached $18.5 million in Q1 2025, marking a 12% increase over the prior year and 5% sequential growth.
Demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products increased, with year-over-year revenue growth of approximately 15% and 2% respectively.
The company commenced a full U.S. commercial launch of larger-sized OviTex PRS for plastic and reconstructive surgery.
TELA Bio reiterated its full year 2025 revenue guidance of $85.0 million to $88.0 million, representing 23% to 27% year-over-year growth.
TELA Bio
TELA Bio
Forward Guidance
TELA Bio reiterated its full year 2025 revenue guidance and expects operating expenses to remain flat compared to 2024.
Positive Outlook
- Full year 2025 revenue is projected to range from $85.0 million to $88.0 million.
- This represents a significant growth of 23% to 27% over full year 2024.
- The company aims to drive higher revenue growth throughout 2025.
- Increased operating leverage is expected.
- The company continues to drive towards profitability.
Challenges Ahead
- 2025 operating expenses are expected to be flat to 2024, which could impact profitability if revenue growth is not as strong as projected.
- The company did not provide specific guidance on net income or EPS for the full year.
- Potential macroeconomic conditions, including recessionary concerns and inflation, could impact business.
- Changes in surgical procedure volumes or frequency due to illness or other factors could affect product demand.
- Supply chain disruptions or pricing pressures could negatively impact financial performance.